Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy

Annals of Internal Medicine

Volumn 126, Issue 2, 1997, Pages 107-115

  Doney, Kristine ^a   Leisenring, Wendy ^a   Storb, Rainer ^a   Appelbaum, Frederick R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; OXYMETHOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031030329     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-2-199701150-00003     Document Type: Article

References (30)

1. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976; 48: 63-70.
2. Storb R, Doney KC Thomas ED, Appelbaum F, Buckner CD, Clift RA, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood. 1982: 59: 236-46.
3. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994; 84: 941-9.
4. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986: 68: 119-25.
5. Storb R, Leisenring W, Deeg HJ, Anasetti C, Appelbaum F, Bensinger W, et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [Letter]. Blood. 1994; 83: 2749-56.
6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974; 18: 295304.
7. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991; 28: 250-9.
8. Doney KC Weiden PL, Storb R, Thomas ED. Treatment of graft-versushost disease in human allogeneic marrow recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol. 1981; 11: 1-8.
9. Deeg HJ, Loughran TP Jr. Storb R, Kennedy MS, Sullivan KM, Doney K, et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation. 1985: 40: 162-6.
10. Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985: 78: 978-83.
11. Deeg HJ, Doney K, Sullivan KM, Loughran TP, Appelbaum F, Kennedy M, et al. Antithymocyte globulin followed by cyclosporine for the treatment of acute GVHD in patients given HLA-identical or -nonidentical marrow grafts. Transplant Proc. 1986; 18: 791-3.
12. Sullivan KM, Witherspoon RP, Storb R, Weiden P. Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988; 72: 546-54.
13. Sullivan KM. Witherspoon RP. Storfa R. Deeg HJ. Dahlberg S, Sanders JE, et al. Alternating-day cyclosporine and prednisone for treatment of highrisk chronic graft-v-host disease. Blood. 1988; 72: 555-61.
14. Doney KC. Weiden PU Buckner CD, Storfa R, Thomas ED. Treatment of severe aplastic anemia using antithymocyte globulin with or without an infusion of HLA haploidentical marrow. Exp Hematol. 1981; 9: 829-34.
15. Doney K, Dahlberg SJ, Monroe D, Storfa R, Buckner CD, Thomas ED. Therapy of severe aplastic anemia with anti-human thymocyte globulin and androgens: the effect of HLA-haploidentical marrow infusion. Blood. 1984; 63: 342-8.
16. Doney K, Storfa R, Buckner CD, McGuffin R, Witherspoon R, Deeg HJ, et al. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol. 1987; 15: 239-42.
17. Doney K, Pepe M, Storfa R, Bryant E, Anasetti C, Appelbaum FR, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone and oxymetholone. Blood. 1992; 79: 2566-71.
18. Doney K, Storfa R, Appelbaum FR, Buckner CD, Sanders J, Singer J, et al. Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. Br J Haematol. 1993; 85: 182-4.
19. Camilla B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, et al. Antithoradc duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983; 62: 883-8.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958; 53: 457-81.
21. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storfa R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. BrJ Haematol. 1993; 83: 602-7.
22. Storfa R, Thomas ED, Buckner CD, Clift RA, Deeg Kl, Fefer A. et al. Marrow transplantation in thirty untransfused patients with severe aplastic anemia. Ann Intern Med. 1980; 92: 30-6.
23. Marsh JC Hows JM. Bryett KA. AI-Hashimi S, Fairhead SM. GordonSmith EC Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987; 70: 1045-52.
24. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. BrJ Haematol. 1988; 70: 177-82.
25. Paquette RL. Tebyani N. Frane M. Ireland P. Ho WG, Champlin RE, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood. 1995; 85: 283-90.
26. Crump M, Larratt LM, Maki E, Curtis JE, Minden MD, Meharchand JM, et al. Treatment of adults with severe aplastic anemia: primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation. Am J Med. 1992; 92: 596-602.
27. Sodé G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991; 78: 277-9.
28. Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988; 69: 413-8.
29. Socié G, Henry-Amar M, Bacigalupo A. Hows J, Tichelli A, LJungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993; 329: 1152-7.
30. Bacigalupo, Breccia G, Codra G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cydosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995: 85: 1348-53.